Loading...
Loading...
CATX| Name | Value |
|---|---|
| Revenues | 1.5M |
| Cost of Revenue | 1.8M |
| Gross Profit | -0.3M |
| Operating Expense | 11.0M |
| Operating I/L | -11.4M |
| Other Income/Expense | 0.0M |
| Interest Income | 0.3M |
| Pretax | -11.1M |
| Income Tax Expense | -0.2M |
| Net Income/Loss | -11.1M |
Perspective Therapeutics, Inc. develops, manufactures, and markets isotope-based medical products and devices for cancer treatment. Its flagship product, CS-1 Cesium-131 brachytherapy seeds, is used for various cancer types including prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. The company generates revenue by selling these products to facilities and physician practices that utilize surgical facilities for cancer treatment.
